Full Press Release Details
YS Biopharma Announces
Results of Extraordinary General Meeting
GAITHERSBURG, Md., May 21, 2024 /PRNewswire/ -- YS Biopharma Co.,
Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today
announced the results of its extraordinary general meeting (the "EGM") held on May 21, 2024 in Hong Kong. Each of the following
resolutions was passed at the EGM:
The Company is attending to the necessary filings with the Registrar
of Companies in Cayman Islands to reflect the change of company name and director appointments. In addition, the Company is working with
the Nasdaq Stock Market LLC to change the trading symbols of its ordinary shares and warrants.
YS Biopharma is a global biopharmaceutical company dedicated
to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases
and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive
and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. YS Biopharma operates
in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information, please visit investor.ysbiopharma.com.
Investor Relations Contact
Director of Investor Relations
Email: ir@yishengbio.com
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com